Company Filing History:
Years Active: 2013-2016
Title: Innovations in Cancer Treatment by Xiaoli Cui
Introduction
Xiaoli Cui is an accomplished inventor based in Memphis, TN (US). She has made significant contributions to the field of cancer research, particularly in developing methods for diagnosing and treating cancers that are resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors. With a total of 2 patents, her work is paving the way for advancements in cancer therapies.
Latest Patents
Xiaoli Cui's latest patents focus on methods and compositions for the diagnosis and treatment of cancer resistant to ALK kinase inhibitors. These inventions are based on the discovery of mutations within ALK that confer resistance to these inhibitors. The patents provide polynucleotides and polypeptides that contain at least one ALK inhibitor resistance mutation. These innovations are crucial for diagnosing, prognosing, and treating diseases associated with aberrant ALK activity, especially those resistant to ALK kinase inhibitors. Additionally, her patents include methods for identifying agents that can inhibit the kinase activity and/or reduce the expression level of the ALK resistance mutants.
Career Highlights
Xiaoli Cui is currently affiliated with St. Jude Children's Research Hospital, where she continues her groundbreaking research. Her work is instrumental in advancing the understanding of cancer resistance mechanisms and developing targeted therapies.
Collaborations
Some of her notable coworkers include Stephan W. Morris and Qin Jiang, who collaborate with her on various research projects aimed at improving cancer treatment outcomes.
Conclusion
Xiaoli Cui's innovative work in cancer research exemplifies the importance of addressing drug resistance in cancer therapies. Her contributions are vital for the future of personalized medicine and improving patient outcomes.